Trial Profile
A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions
- Sponsors Amgen
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Dec 2016 This trial has been completed in Czech Republic.
- 26 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Mar 2017.